Thierry Legon

ASIT Biotech (Belgium) — Belgium

Medicine · Health Sciences

5h-index192citations12works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Allergic Rhinitis and Sensitization(9), Food Allergy and Anaphylaxis Research(7), Asthma and respiratory diseases(6), Dermatology and Skin Diseases(4), Pediatric health and respiratory diseases(2)

Publications12 total

Immunologic mechanisms of a short-course of Lolium perenne peptide immunotherapy: A randomized, double-blind, placebo-controlled trial
Journal of Allergy and Clinical Immunology·2019· 50 citedOpen Access
Immunomodulatory properties of lolium perenne peptides for the treatment of seasonal allergic rhinitis
Ghent University Academic Bibliography (Ghent University)·2019
Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial
Allergy·2018· 49 citedOpen Access
Short Course of Lolium Perenne Peptides (LPP) Immunotherapy Deletes Circulating IL-4 + IL-21 + T follicular helper cells and Induces FoxP3 + T follicular regulatory cells: A Randomized Controlled Trial
Journal of Allergy and Clinical Immunology·2018
Quality of Life during the hay fever season after short-course subcutaneous immunotherapy with Lolium perenne peptides (LPP) in grass pollen related rhinoconjunctivitis: A RDBPCT
Journal of Allergy and Clinical Immunology·2018
Short Course of Lolium Perenne Peptides (LPP) Immunotherapy Induces IL-35+ T Regulatory Cells (iTr35) that Promote B Regulatory Cells (Bregs) and Blocking Antibodies
Journal of Allergy and Clinical Immunology·2018
<i>Lolium perenne</i> peptide immunotherapy is well tolerated and elicits a protective B‐cell response in seasonal allergic rhinitis patients
Allergy·2018· 30 citedOpen Access
A randomized, double‐blind, placebo‐controlled, dose‐finding trial with <i>Lolium perenne</i> peptide immunotherapy
Allergy·2017· 34 citedOpen Access
Lolium perenne peptides for treatment of grass pollen allergy: A randomized, double-blind, placebo-controlled clinical trial
Journal of Allergy and Clinical Immunology·2017· 25 citedOpen Access
Immunological biomarker predict clinical effects in subcutaneous peptide allergen immunotherapy
Kölner Universitäts PublikationsServer (Universität zu Köln)·2016
Immunogenicity Evaluation of Subcutaneous Administration of Peptide Hydrolysate from Lolium Perenne (gpASIT+™) in Combination with Bacterial HSP70 (DnaK) in Patients with Seasonal Allergic Rhinitis: A Double Blind Placebo Controlled Trial
Journal of Allergy and Clinical Immunology·2015Open Access
Immunogenicity evaluation of subcutaneous administration of peptide hydrolysate from Lolium perenne (gpASIT plus TM) in combination with bacterial HSP70 (DnaK) in patients with seasonal allergic rhinitis
Allergy·2014· 4 cited

Frequent Co-authors

Sabine Pirotton(12), Stephen R. Durham(11), Mohamed H. Shamji(11), Ralph Mösges(9), Claus Bachert(7), Jean Duchateau(6), Hanisah Sharif(4), Iesha Singh(4), Lubna Kouser(4), Rebecca Parkin(4), Gabriële Holtappels(4), R. von Frenckell(4), Nathalie Wathelet(4), L. Haazen(4), Marie-Alix Bonny(3), Angeliki Karamani(3), Nicolas Bovy(3), Abigail Robb(3), Lara Derycke(3), A. Astvatsatourov(3)